Asthma: How Bloodwork Flags Airway Inflammation

REVIEWED BY

William Maish, MD MBA MPH

Clinical Product Lead

Published

Last updated

Key takeaway:

Blood testing for asthma measures eosinophils and CRP to characterize airway inflammation type and intensity. Elevated eosinophils (often ≥150–300 cells/µL) indicate type 2 inflammation and may help support biologic eligibility decisions, while elevated CRP flags exacerbation or systemic factors. Tracking these markers over time is associated with refined phenotyping and exacerbation risk assessment.

Read more →

Understand what your immune health results really mean

See your biomarkers in context with a comprehensive panel.

  • CLIA-certified labs
  • HIPAA compliant
  • Personalized health protocol
Book your test

Asthma and the inflammatory signals behind it

Asthma biomarkers are measurable signals in your blood that mirror the inflammation inside your airways. Blood testing highlights the immune pathways that tighten and swell the bronchial tubes, helping distinguish asthma driven by allergy-type inflammation from other patterns. Key players include eosinophils (a type of white blood cell) and allergic antibodies (IgE), which rise when type 2 immune responses are active (T2 inflammation). These arise from immune cells and the airway lining and reflect the release of inflammatory messengers (cytokines such as IL‑5 and IL‑13) that promote mucus production, airway sensitivity, and flare‑ups. Additional blood proteins from the airway-epithelial response (periostin) can also signal this biology. By capturing this internal story, biomarkers make invisible airway inflammation visible—showing how “hot” the disease is, how likely symptoms or exacerbations are, and which biologic targets may be relevant. In short, asthma biomarkers translate complex airway immune activity into objective clues your clinician can use to characterize the disease and personalize care.

Join 150,000+ others building better health

Get the science behind better health, every week.

By clicking “Subscribe” you agree to our Terms of Service and Privacy Policy.

Why eosinophils and CRP help phenotype asthma

Asthma blood biomarkers are signals from the immune and inflammatory systems that reveal how “hot” the airways and the whole body are. They help distinguish allergic, type 2–driven asthma from irritant- or infection-predominant patterns, anticipate flares, and show how much inflammation spills beyond the lungs into metabolism and the cardiovascular system. Two common labs matter here. Eosinophils, the allergy‑linked white cells, typically sit in the low single‑digit percent range (about 1–4%) or with absolute counts below about 0.5. CRP, a marker of whole‑body inflammation, is usually below about 3, and is healthiest toward the low end. When eosinophils rise, it points to type 2 airway inflammation, mucus overproduction, and a higher chance of wheeze, nighttime symptoms, and sinus/eczema clustering. Higher CRP suggests broader inflammatory stress—from an exacerbation, infection, obesity, or comorbid disease—and may come with fatigue, malaise, and greater cardiometabolic strain. When these values are low, they often reflect quiet airway biology. Low eosinophils indicate little allergic (eosinophilic) activity; symptoms, if present, may be cough and chest tightness with irritants, cold air, or viruses rather than classic allergy triggers. Low CRP supports a low systemic inflammatory load. Children with allergic tendencies more often show higher eosinophils; in pregnancy, CRP can run modestly higher even without infection. Big picture, these biomarkers connect the lungs to immune, metabolic, and vascular networks. Tracking them over time helps clarify asthma phenotype, risks for exacerbations and airway remodeling, and how much the condition interacts with sinus disease, atopic skin issues, weight, and long‑term heart and lung health.

Test 100+ biomarkers from home

One blood draw. A full picture of your health, explained in plain language.

Book your test

What these markers add to an asthma picture

Asthma blood testing provides insight into how your immune system is functioning and how it may be influencing your overall health. Asthma is not just a lung condition—it’s a reflection of how your body manages inflammation and immune responses, which can affect energy, metabolism, cardiovascular health, and even cognitive function. At Superpower, we focus on two key biomarkers for asthma: Eosinophils and C-reactive protein (CRP).Eosinophils are a type of white blood cell involved in allergic reactions and defense against certain infections. In asthma, eosinophils can become elevated, signaling that the immune system is reacting strongly—sometimes too strongly—to environmental triggers. CRP is a protein produced by the liver in response to inflammation anywhere in the body. While CRP is not specific to asthma, higher levels can indicate ongoing inflammation, which is often present during asthma flare-ups or poorly controlled disease. Healthy levels of eosinophils suggest that the immune system is balanced and not overreacting, which supports stable airway function and reduces the risk of asthma symptoms. Similarly, a low CRP level indicates minimal systemic inflammation, which is associated with better respiratory health and overall stability. Together, these markers help reveal whether the body’s inflammatory and immune responses are under control, which is essential for maintaining healthy lung function in asthma. Interpretation of these biomarkers can be influenced by factors such as recent infections, allergies, age, pregnancy, and certain medications like steroids. Laboratory methods and reference ranges may also vary, so results are best understood in the context of your overall health and medical history.

Frequently Asked Questions

References

  1. Lambrecht BN, Hammad H (2015). The immunology of asthma. *Nature Immunology*, *16*(1), 45-56. https://doi.org/10.1038/ni.3049
  2. Wenzel SE (2012). Asthma phenotypes: The evolution from clinical to molecular approaches. *Nature Medicine*, *18*(5), 716-725. https://doi.org/10.1038/nm.2678
  3. Price DB, Rigazio A, Campbell JD, Bleecker ER, Corrigan CJ, Thomas M, Wenzel SE, Wilson AM, Small MB, Gopalan G, Ashton VL, Burden A, Hillyer EV, Kerkhof M, Pavord ID (2015). Blood eosinophil count and prospective annual asthma disease burden: A UK cohort study. *The Lancet. Respiratory Medicine*, *3*(11), 849-858. https://doi.org/10.1016/S2213-2600(15)00367-7
  4. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, Boulet LP, Brightling C, Chanez P, Dahlen SE, Djukanovic R, Frey U, Gaga M, Gibson P, Hamid Q, ... Teague WG (2014). International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *The European Respiratory Journal*, *43*(2), 343-373. https://doi.org/10.1183/09031936.00202013
  5. Hill DA, Spergel JM (2018). The atopic march: Critical evidence and clinical relevance. *Annals of Allergy, Asthma & Immunology*, *120*(2), 131-137. https://doi.org/10.1016/j.anai.2017.10.037

Led by doctors with 40 years of health and longevity expertise

Dr. Anant Vinjamoori

Dr. Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Dr. Leigh Erin Connealy

Dr. Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Dr. Robert Lufkin

Dr. Robert Lufkin, MD

Physician & UCLA Medical School Professor, NYT bestselling author

Dr. Abe Malkin

Dr. Abe Malkin, MD

Founder & Medical Director of Concierge MD

Membership 1
1 / 4

Your membership starts here

Annual 100+ biomarker panel

  • Data dashboard and digital twin
  • Upload past labs and connect wearables
  • Personalized health protocol
  • 24/7 care team access
  • AI companion for all health questions
  • Marketplace with additional solutions
$199
/year*Billed annually
Get started
HSA/FSA eligibleCancel anytimeResults in a week

*Pricing may vary for members in New York and New Jersey